Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out
In This Article:
Large-cap players including Gilead Sciences Amgen AbbVie Johnson & Johnson and Eli Lilly have seen inflows that nudged their share prices disproportionately higher. While Gilead, Amgen AbbVie and Johnson & Johnson have trailed the for the past three years, the analyst says there is room for upside in the near term and lifted the stocks’ price targets accordingly. Shares were up 0.2% to $115 on Wednesday, with the new price target suggesting a potential upside of just under 10%.
Terms and Privacy Policy